[{"id":"06a32ccb-2e76-4068-b6c6-069ccedeb90b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05979792","created_at":"2023-08-07T14:09:05.739Z","updated_at":"2024-07-02T16:35:39.618Z","phase":"Phase 1","brief_title":"Clinical Study of CD7 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory CD7-positive Peripheral T Cell Lymphoma","source_id_and_acronym":"NCT05979792","lead_sponsor":"Zhao Weili","biomarkers":" CD7","pipe":"","alterations":" ","tags":["CD7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CTD-402"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 09/01/2023","start_date":" 09/01/2023","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-08-21"},{"id":"c596e795-0c84-4e8a-a444-a69c114e44e1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05923541","created_at":"2023-06-28T14:08:39.746Z","updated_at":"2024-07-02T16:35:44.491Z","phase":"Phase 1","brief_title":"RD13-02 for Patients With r/r CD7+ T Cell Hematologic Malignancies","source_id_and_acronym":"NCT05923541","lead_sponsor":"Henan Cancer Hospital","biomarkers":" CD7","pipe":"","alterations":" ","tags":["CD7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CTD-402"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 06/30/2023","start_date":" 06/30/2023","primary_txt":" Primary completion: 06/07/2025","primary_completion_date":" 06/07/2025","study_txt":" Completion: 06/07/2026","study_completion_date":" 06/07/2026","last_update_posted":"2023-06-28"},{"id":"b60b52d1-2eea-4937-bd89-c85f79d85b61","acronym":"","url":"https://clinicaltrials.gov/study/NCT05907603","created_at":"2023-06-18T18:08:18.379Z","updated_at":"2024-07-02T16:35:45.413Z","phase":"Phase 1","brief_title":"Research Development（RD）13-02 Chimeric Antigen Receptor(CAR) -T Cell Injection for Patients With r/r Cluster Of Differentiation 7（CD7）+ T-Acute Lymphoblastic Leukemia(ALL)/T-Lymphoblastic Lymphoma(LBL) /Acute Myelogenous Leukemia(AML)","source_id_and_acronym":"NCT05907603","lead_sponsor":"Kai Lin Xu，MD","biomarkers":" CD7","pipe":"","alterations":" ","tags":["CD7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CTD-402"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 03/08/2023","start_date":" 03/08/2023","primary_txt":" Primary completion: 03/08/2024","primary_completion_date":" 03/08/2024","study_txt":" Completion: 03/08/2025","study_completion_date":" 03/08/2025","last_update_posted":"2023-06-16"},{"id":"f8291e00-348f-476f-9633-f54bedbe3402","acronym":"","url":"https://clinicaltrials.gov/study/NCT05902845","created_at":"2023-06-15T18:08:45.738Z","updated_at":"2024-07-02T16:35:45.748Z","phase":"Phase 1","brief_title":"RD13-02 CAR-T Cell Injection for Patients With r/r CD7+ T-ALL/T-LBL","source_id_and_acronym":"NCT05902845","lead_sponsor":"Xiaoyu Zhu","biomarkers":" CD7","pipe":"","alterations":" ","tags":["CD7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CTD-402"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 04/30/2023","start_date":" 04/30/2023","primary_txt":" Primary completion: 04/30/2024","primary_completion_date":" 04/30/2024","study_txt":" Completion: 04/30/2025","study_completion_date":" 04/30/2025","last_update_posted":"2023-06-14"},{"id":"f2f1bb30-be73-46d6-a976-5541a2a0cffa","acronym":"","url":"https://clinicaltrials.gov/study/NCT05895994","created_at":"2023-06-09T16:06:40.550Z","updated_at":"2024-07-02T16:35:46.044Z","phase":"Phase 1","brief_title":"Research Development13(RD13)-02 Cell Injection in Patients With Relapsed or Refractory Cluster Of Differentiation 7(CD7)-Positive Hematological Malignancies","source_id_and_acronym":"NCT05895994","lead_sponsor":"MEI HENG","biomarkers":" CD7","pipe":"","alterations":" ","tags":["CD7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CTD-402"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 03/10/2023","start_date":" 03/10/2023","primary_txt":" Primary completion: 02/20/2025","primary_completion_date":" 02/20/2025","study_txt":" Completion: 02/20/2026","study_completion_date":" 02/20/2026","last_update_posted":"2023-06-09"},{"id":"e38d0160-f9a3-453e-abce-9817f0fd7fa4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05716113","created_at":"2023-02-08T18:00:16.498Z","updated_at":"2024-07-02T16:35:56.269Z","phase":"Phase 1","brief_title":"CD7 CAR-T for Patients With r/r CD7+ T-ALL/T-LBL","source_id_and_acronym":"NCT05716113","lead_sponsor":"He Huang","biomarkers":" CD7","pipe":"","alterations":" ","tags":["CD7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CTD-402"],"overall_status":"Recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 02/15/2023","start_date":" 02/15/2023","primary_txt":" Primary completion: 03/20/2024","primary_completion_date":" 03/20/2024","study_txt":" Completion: 05/20/2025","study_completion_date":" 05/20/2025","last_update_posted":"2023-02-07"}]